TY  - JOUR
AU  - Kamusheva, Maria
AU  - Georgieva, Svetla
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Stoimenova, Assena
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1965
AB  - The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria
VL  - 27
IS  - 3
SP  - 3896
EP  - 3900
DO  - 10.5504/BBEQ.2013.0029
ER  - 

@article{
author = "Kamusheva, Maria and Georgieva, Svetla and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Stoimenova, Assena and Petrova, Guenka",
year = "2013",
abstract = "The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria",
volume = "27",
number = "3",
pages = "3896-3900",
doi = "10.5504/BBEQ.2013.0029"
}

Kamusheva, M., Georgieva, S., Lakić, D., Mitov, K., Savova, A., Stoimenova, A.,& Petrova, G.. (2013). A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 27(3), 3896-3900.
https://doi.org/10.5504/BBEQ.2013.0029

Kamusheva M, Georgieva S, Lakić D, Mitov K, Savova A, Stoimenova A, Petrova G. A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment. 2013;27(3):3896-3900.
doi:10.5504/BBEQ.2013.0029 .

Kamusheva, Maria, Georgieva, Svetla, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Stoimenova, Assena, Petrova, Guenka, "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria" in Biotechnology & Biotechnological Equipment, 27, no. 3 (2013):3896-3900,
https://doi.org/10.5504/BBEQ.2013.0029 . .

TY  - JOUR
AU  - Lakić, Dragana
AU  - Tasić, Ljiljana
AU  - Kos, Mitja
AU  - Petrova, Guenka
AU  - Stoimenova, Assena
AU  - Krajnović, Dušanka
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1692
AB  - Aim To analyze the pharmacy network (structure and resources) in Bulgaria, Croatia, Serbia, and Slovenia and its relation to public expenditures for medicines. Methods We performed a cross-sectional study using the officially published data for the period 2003-2008 in four selected countries. Data sources were relevant national institutions. Results In 2008, Serbia had 27.5, Bulgaria 66.8, Croatia 59.5, and Slovenia 71.2 pharmacists per 100000 inhabitants. There was a significant difference in the number of pharmacists per 100000 inhabitants between all countries except between Bulgaria and Slovenia. The number of inhabitants per one pharmacy was significantly different between all observed countries. The expenditures for medicines per capita in 2008 were between (sic)30.34 in Bulgaria to (sic)137.03 in Slovenia, with a significant difference between all countries except between Bulgaria and Serbia. The number of pharmacists per 100000 inhabitants and expenditures for medicines per capita were positively correlated in all observed countries, except in Bulgaria. Conclusion There were significant difference in the structure and availability of the pharmacy service in all selected countries. Expenditures for medicines were positively correlated with the number of pharmacists in all countries, except in Bulgaria. Our findings could be valuable to national regulatory bodies for the creation of national drug policies.
PB  - Medicinska Naklada, Zagreb
T2  - Croatian Medical Journal
T1  - Pharmacy network and access to medicines in selected eastern European countries: comparative analysis
VL  - 53
IS  - 1
SP  - 53
EP  - 59
DO  - 10.3325/cmj.2012.53.53
ER  - 

@article{
author = "Lakić, Dragana and Tasić, Ljiljana and Kos, Mitja and Petrova, Guenka and Stoimenova, Assena and Krajnović, Dušanka",
year = "2012",
abstract = "Aim To analyze the pharmacy network (structure and resources) in Bulgaria, Croatia, Serbia, and Slovenia and its relation to public expenditures for medicines. Methods We performed a cross-sectional study using the officially published data for the period 2003-2008 in four selected countries. Data sources were relevant national institutions. Results In 2008, Serbia had 27.5, Bulgaria 66.8, Croatia 59.5, and Slovenia 71.2 pharmacists per 100000 inhabitants. There was a significant difference in the number of pharmacists per 100000 inhabitants between all countries except between Bulgaria and Slovenia. The number of inhabitants per one pharmacy was significantly different between all observed countries. The expenditures for medicines per capita in 2008 were between (sic)30.34 in Bulgaria to (sic)137.03 in Slovenia, with a significant difference between all countries except between Bulgaria and Serbia. The number of pharmacists per 100000 inhabitants and expenditures for medicines per capita were positively correlated in all observed countries, except in Bulgaria. Conclusion There were significant difference in the structure and availability of the pharmacy service in all selected countries. Expenditures for medicines were positively correlated with the number of pharmacists in all countries, except in Bulgaria. Our findings could be valuable to national regulatory bodies for the creation of national drug policies.",
publisher = "Medicinska Naklada, Zagreb",
journal = "Croatian Medical Journal",
title = "Pharmacy network and access to medicines in selected eastern European countries: comparative analysis",
volume = "53",
number = "1",
pages = "53-59",
doi = "10.3325/cmj.2012.53.53"
}

Lakić, D., Tasić, L., Kos, M., Petrova, G., Stoimenova, A.,& Krajnović, D.. (2012). Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. in Croatian Medical Journal
Medicinska Naklada, Zagreb., 53(1), 53-59.
https://doi.org/10.3325/cmj.2012.53.53

Lakić D, Tasić L, Kos M, Petrova G, Stoimenova A, Krajnović D. Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. in Croatian Medical Journal. 2012;53(1):53-59.
doi:10.3325/cmj.2012.53.53 .

Lakić, Dragana, Tasić, Ljiljana, Kos, Mitja, Petrova, Guenka, Stoimenova, Assena, Krajnović, Dušanka, "Pharmacy network and access to medicines in selected eastern European countries: comparative analysis" in Croatian Medical Journal, 53, no. 1 (2012):53-59,
https://doi.org/10.3325/cmj.2012.53.53 . .